Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant, retaining the price target of $50.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sam Slutsky has given his Buy rating due to a combination of factors including Immunovant’s progress in their late-stage programs and promising clinical data. The company is actively advancing its pipeline of subcutaneous FcRn inhibitors, with IMVT-1402 maintaining its clinical timelines, which indicates strong execution capabilities.
Additionally, recent data from the Phase 2a study of batoclimab for Graves’ Disease showed encouraging results, with a significant percentage of patients achieving normal thyroid function and some achieving remission. This positive efficacy signal, coupled with the potential market opportunity for IMVT-1402, supports the Buy rating.
Slutsky covers the Healthcare sector, focusing on stocks such as Celldex, Palvella Therapeutics, and Astria Therapeutics. According to TipRanks, Slutsky has an average return of 27.4% and a 48.77% success rate on recommended stocks.
In another report released on November 9, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.